First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm

Christos Stafylidis, Eleni Variami, Eleftheria Lakiotaki, Iraklis Patsialos, Stavroula Syriopoulou, Konstantinos Sideris, Christina-Nefeli Kontandreopoulou, Dimitra Vlachopoulou, Sofia Stouggioti, Elena Solomou, Michaela Plaka, Nikos Georgakopoulos, Penelope Korkolopoulou, Marina Mantzourani, Panagiotis Diamantopoulos

Open source

DOI: 10.1080/10428194.2026.2757354
Published: 2026-11-02
Container: Leukemia & Lymphoma
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2026.2757354,
  title = {First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm},
  author = {Christos Stafylidis and Eleni Variami and Eleftheria Lakiotaki and Iraklis Patsialos and Stavroula Syriopoulou and Konstantinos Sideris and Christina-Nefeli Kontandreopoulou and Dimitra Vlachopoulou and Sofia Stouggioti and Elena Solomou and Michaela Plaka and Nikos Georgakopoulos and Penelope Korkolopoulou and Marina Mantzourani and Panagiotis Diamantopoulos},
  year = {2026},
  journal = {Leukemia \&amp; Lymphoma},
  doi = {10.1080/10428194.2026.2757354},
  url = {https://doi.org/10.1080/10428194.2026.2757354}
}

RIS

TY  - JOUR
TI  - First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm
AU  - Christos Stafylidis
AU  - Eleni Variami
AU  - Eleftheria Lakiotaki
AU  - Iraklis Patsialos
AU  - Stavroula Syriopoulou
AU  - Konstantinos Sideris
AU  - Christina-Nefeli Kontandreopoulou
AU  - Dimitra Vlachopoulou
AU  - Sofia Stouggioti
AU  - Elena Solomou
AU  - Michaela Plaka
AU  - Nikos Georgakopoulos
AU  - Penelope Korkolopoulou
AU  - Marina Mantzourani
AU  - Panagiotis Diamantopoulos
PY  - 2026
JO  - Leukemia &amp; Lymphoma
DO  - 10.1080/10428194.2026.2757354
UR  - https://doi.org/10.1080/10428194.2026.2757354
ER  -

APA

Stafylidis, C., Variami, E., Lakiotaki, E., Patsialos, I., Syriopoulou, S., Sideris, K., Kontandreopoulou, C., Vlachopoulou, D., Stouggioti, S., Solomou, E., Plaka, M., Georgakopoulos, N., Korkolopoulou, P., Mantzourani, M., & Diamantopoulos, P. (2026). First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2026.2757354

Source records

crossref · retrieved 2026-11-08T22:37:59.152Z